- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04393415
Using PRP and Cord Blood in Treatment of Covid -19
July 24, 2020 updated by: Aljazeera Hospital
the Effect of PRP and Cord Blood in Improving the Symptoms of Covid-19
covid - 19 is a critical viral infection that affects humans
Study Overview
Detailed Description
Covid -19 pandemic started was declared in 2020
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Giza, Egypt
- Recruiting
- Aljazeera( Al Gazeera) hospital
-
Contact:
- Mahmoud Alalfy, PhD
- Phone Number: +2 +201002611058
- Email: mahmoudalalfy@ymail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients with positive covid -19 and has symptoms and isolated in the hospital
Exclusion Criteria:
- patients with negative test for covid -19
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: patients receiving LGF
|
giving stem cells to patients with covid - 19
|
|
No Intervention: patients not receiving LGF nor PRP
|
|
|
Active Comparator: patients receiving Platelet rich plasma
|
giving stem cells to patients with covid - 19
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the number of patients with positive covid 19 who will improve after receiving stem cells
Time Frame: 2 weeks
|
patients with positive covid 19 who will improve after receiving stem cells
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 25, 2020
Primary Completion (Anticipated)
August 25, 2020
Study Completion (Anticipated)
September 1, 2020
Study Registration Dates
First Submitted
May 15, 2020
First Submitted That Met QC Criteria
May 15, 2020
First Posted (Actual)
May 19, 2020
Study Record Updates
Last Update Posted (Actual)
July 27, 2020
Last Update Submitted That Met QC Criteria
July 24, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- covid -19
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Virus
-
ModernaTX, Inc.RecruitingEpstein-Barr VirusAustralia
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingHealthy Volunteers | Epstein-Barr Virus (EBV)Australia
-
Vaccine Company, Inc.Not yet recruiting
-
Suzhou Abogen Biosciences Co., Ltd.Abogen Biosciences (Shanghai) Co., LtdActive, not recruitingVaricella-zoster VirusChina
-
Suzhou Abogen Biosciences Co., Ltd.Abogen Biosciences (Shanghai) Co., LtdActive, not recruitingVaricella-zoster VirusChina
-
Institute of Tropical Medicine, BelgiumCompletedTransmission | Zika Virus | Zika Virus Disease | Virus SheddingBelgium
-
TakedaCompletedFlavivirus Infections | Healthy Participants | Virus, Zika | Zika Virus DiseaseUnited States, Puerto Rico
-
Jennifer AmengualNot yet recruitingSolid Organ Transplant | Epstein Barr Virus (EBV) Infection | PTLD
-
Institute of Hematology & Blood Diseases Hospital...Not yet recruitingEBV Infection | HSCT
-
Centre Hospitalier Universitaire de NīmesCompletedEpstein-Barr Virus Infections | Radiologically Isolated SyndromeFrance
Clinical Trials on stem cells
-
University College, LondonUnknownTendinopathy | Achilles Tendinitis | Achilles Degeneration | Achilles Tendinitis, Right Leg | Achilles Tendon Thickening | Achilles Tendinitis, Left LegUnited Kingdom
-
StemCells, Inc.WithdrawnNeuronal Ceroid LipofuscinosisUnited States
-
Hadassah Medical OrganizationCompletedAmyotrophic Lateral Sclerosis
-
Honya Medical IncChang Gung Memorial HospitalNot yet recruitingCoronary Artery DiseaseTaiwan
-
El-Rayadh Fertility CentreUnknownPremature Ovarian FailureEgypt
-
National Research Center for Hematology, RussiaUnknownRelapse | Graft-versus-host DiseaseRussian Federation
-
Hospital ZnojmoUnknown
-
Guangzhou General Hospital of Guangzhou Military...UnknownParkinson's DiseaseChina
-
Guangzhou General Hospital of Guangzhou Military...UnknownSpinal Cord InjuryChina
-
Guangzhou General Hospital of Guangzhou Military...Guangzhou Municipal Twelfth People's Hospital; Guangdong Prevention and Treatment...Unknown